Profile cover photo
Profile photo
Matinas BioPharma
13 followers -
Matinas is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications.
Matinas is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications.

13 followers
About
Posts

Post has attachment
Matinas today announced that investigators from the National Institutes of Health (“NIH”) have relayed to the Company positive data from a third patient enrolled in the collaborative Phase 2a clinical study of Matinas’ lead anti- infective product candidate MAT2203 for the treatment of chronic refractory mucocutaneous candidiasis (“CMC”) infection. This third patient, with long-standing azole resistant mucocutaneous candidiasis, met the primary endpoint of the Phase 2a study in achieving ≥ 50% clinical response with treatment of MAT2203. MAT2203 was well tolerated with any adverse events observed being mild in severity and unrelated to study drug. With this third positive response, the study has met its statistical hurdle for success. Read today's press release for full details:
Add a comment...

Post has attachment
Happy holidays from the Matinas team!
Photo
Add a comment...

Post has attachment
Matinas announced the appointment of Matthew A. Wikler, M.D., M.B.A., FIDSA, to its Board of Directors. Dr. Wikler will replace current Board member, Stefano Ferrari, effective January 1, 2018. Dr. Wikler is a senior healthcare physician executive and therapeutic expert in infectious diseases, who has successfully and ethically developed multiple pharmaceutical products in the biopharmaceutical industry over the past thirty-three years of his career. Learn more about Dr. Wikler in today's press release:
Add a comment...

Post has attachment
Infections that happen because a person’s immune system is weak are called opportunistic infections. These illnesses can be caused by bacteria, viruses, or fungi. Learn more from CDC here:
Add a comment...

Post has attachment

Post has attachment

Post has attachment

Post has attachment
Fungal infections are responsible for approximately 150 deaths every hour worldwide and cause more deaths than tuberculosis and malaria. Learn more:
Add a comment...

Post has attachment

Post has attachment
Data from our VVC study and interim data from an NIH study of MAT2203 have strengthened the validation of our cochleate technology for safe and efficacious delivery of drug.
Photo
Add a comment...
Wait while more posts are being loaded